Document is current
Any future updates will be listed below
-
Authors
Ebina, Junya
Mizumura, Sunao
Ishii, Nobutomo
Kobayashi, Yukio
Shibukawa, Mari
Morioka, Harumi
Nagasawa, Junpei
Yanagihashi, Masaru
Hirayama, Takehisa
Kawabe, Kiyokazu
Orimo, Satoshi
Kano, Osamu https://orcid.org/0000-0003-3748-3694
- License Information
-
More Information
Article History
Received: 8 February 2023
Revised: 2 May 2023
Accepted: 8 May 2023
First Online: 24 May 2023
Declarations
:
: O.K. received honoraria from AbbVie GK, Alexion Pharmaceuticals, Inc., Biogen Japan Ltd., Biogen, Inc., Chugai Pharmaceuticals Co., Ltd., Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd., scholarship grants from Eisai Co., Ltd., and Otsuka Pharmaceutical Co., Ltd., and writing fees from Mitsubishi Tanabe Pharma Co., outside the submitted work, and grants for commissioned work from Alexion Pharmaceuticals, Inc., and Mitsubishi Tanabe Pharma Co. S.O. received honoraria from Eisai Co., Ltd. and Sumitomo Pharma Co., Ltd.
: This study was approved by the Ethics Committee of Toho University Omori Medical Center (M20101, M22232) and conducted according to the Declaration of Helsinki.
